prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |review
The inactivated vaccine consists of three strains, two of influenza A (H3N2, H1N1) and one of influenza B. The strains included represent the most recent antigenic variants. The strains in the vaccine for the 2000-2001 season are A/Panama/2007/99 (H3N2)-like, A/New Caledonia/20/99 (H1N1)-like, B/Yamanashi/166/98. The viruses are grown in embryonated eggs and are noninfectious. The vaccine is approximately 70-80% effective dependent on the age and immunocompetence of the vaccine recipient and the similarity between the virus strains in the vaccine and those circulating in the community. When the match is close, the effectiveness is at least 70 %. The vaccine is safe. The only contraindication is allergy to eggs and other components in the vaccine. Soreness at the site of injection is the most common complaint. Fever, malaise and myalgia are infrequent. The vaccine should be given each year prior to the influenza season. Live influenza vaccine, given intranasally, has been shown by clinical trials to be effective and safe. However, it is not commercially available.